Literature DB >> 31004032

Pre-treatment CD38-positive regulatory T cells affect the durable response to daratumumab in relapsed/refractory multiple myeloma patients.

Akihiro Kitadate1, Hiroki Kobayashi2, Yoshiaki Abe2, Kentaro Narita2, Daisuke Miura2, Masami Takeuchi2, Kosei Matsue2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31004032      PMCID： PMC6939519          DOI： 10.3324/haematol.2019.219683

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib.

Authors:  Inger S Nijhof; Richard W J Groen; Willy A Noort; Berris van Kessel; Regina de Jong-Korlaar; Joost Bakker; Jeroen J L van Bueren; Paul W H I Parren; Henk M Lokhorst; Niels W C J van de Donk; Anton C M Martens; Tuna Mutis
Journal:  Clin Cancer Res       Date:  2014-11-14       Impact factor: 12.531

2.  Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells.

Authors:  M C Minnema; M S van der Veer; T Aarts; M Emmelot; T Mutis; H M Lokhorst
Journal:  Leukemia       Date:  2008-09-11       Impact factor: 11.528

3.  Long-term CD38 saturation by daratumumab interferes with diagnostic myeloma cell detection.

Authors:  Anna Oberle; Anna Brandt; Malik Alawi; Claudia Langebrake; Snjezana Janjetovic; Christine Wolschke; Kerstin Schütze; Peter Bannas; Nicolaus Kröger; Friedrich Koch-Nolte; Carsten Bokemeyer; Mascha Binder
Journal:  Haematologica       Date:  2017-05-18       Impact factor: 9.941

4.  A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.

Authors:  Thomas Martin; Rachid Baz; Don M Benson; Nikoletta Lendvai; Jeffrey Wolf; Pamela Munster; Alexander M Lesokhin; Claudine Wack; Eric Charpentier; Frank Campana; Ravi Vij
Journal:  Blood       Date:  2017-05-08       Impact factor: 22.113

5.  Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma.

Authors:  Xiaoyan Feng; Li Zhang; Chirag Acharya; Gang An; Kenneth Wen; Lugui Qiu; Nikhil C Munshi; Yu-Tzu Tai; Kenneth C Anderson
Journal:  Clin Cancer Res       Date:  2017-03-01       Impact factor: 12.531

6.  Treatment with lenalidomide induces immunoactivating and counter-regulatory immunosuppressive changes in myeloma patients.

Authors:  A Busch; D Zeh; V Janzen; L-O Mügge; D Wolf; L Fingerhut; C Hahn-Ast; O Maurer; P Brossart; M von Lilienfeld-Toal
Journal:  Clin Exp Immunol       Date:  2014-08       Impact factor: 4.330

7.  Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma.

Authors:  Antonio Palumbo; Asher Chanan-Khan; Katja Weisel; Ajay K Nooka; Tamas Masszi; Meral Beksac; Ivan Spicka; Vania Hungria; Markus Munder; Maria V Mateos; Tomer M Mark; Ming Qi; Jordan Schecter; Himal Amin; Xiang Qin; William Deraedt; Tahamtan Ahmadi; Andrew Spencer; Pieter Sonneveld
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

8.  Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma.

Authors:  Jakub Krejcik; Tineke Casneuf; Inger S Nijhof; Bie Verbist; Jaime Bald; Torben Plesner; Khaja Syed; Kevin Liu; Niels W C J van de Donk; Brendan M Weiss; Tahamtan Ahmadi; Henk M Lokhorst; Tuna Mutis; A Kate Sasser
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

9.  Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma.

Authors:  Ajai Chari; Attaya Suvannasankha; Joseph W Fay; Bertrand Arnulf; Jonathan L Kaufman; Jainulabdeen J Ifthikharuddin; Brendan M Weiss; Amrita Krishnan; Suzanne Lentzsch; Raymond Comenzo; Jianping Wang; Kerri Nottage; Christopher Chiu; Nushmia Z Khokhar; Tahamtan Ahmadi; Sagar Lonial
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

10.  Deep sustained response to daratumumab monotherapy associated with T-cell expansion in triple refractory myeloma.

Authors:  Saad Z Usmani; Imran Khan; Christopher Chiu; David Foureau; Lawrence J Druhan; Katherine Rigby; Tineke Casneuf; A Kate Sasser
Journal:  Exp Hematol Oncol       Date:  2018-02-07
View more
  9 in total

Review 1.  Practical guidance for new multiple myeloma treatment regimens: A nursing perspective.

Authors:  Monica Epstein; Candis Morrison
Journal:  Semin Oncol       Date:  2022-02-10       Impact factor: 5.385

2.  The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models.

Authors:  Shih-Feng Cho; Liang Lin; Lijie Xing; Yuyin Li; Kenneth Wen; Tengteng Yu; Phillip A Hsieh; Nikhil Munshi; Joachim Wahl; Katja Matthes; Matthias Friedrich; Tara Arvedson; Kenneth C Anderson; Yu-Tzu Tai
Journal:  Blood Adv       Date:  2020-09-08

Review 3.  Antibody-Based Treatment Approaches in Multiple Myeloma.

Authors:  Hitomi Hosoya; Surbhi Sidana
Journal:  Curr Hematol Malig Rep       Date:  2021-03-17       Impact factor: 3.952

Review 4.  Immunotherapy for Multiple Myeloma.

Authors:  Hideto Tamura; Mariko Ishibashi; Mika Sunakawa; Koiti Inokuchi
Journal:  Cancers (Basel)       Date:  2019-12-12       Impact factor: 6.639

5.  Low clinical protective response to SARS-CoV-2 mRNA COVID-19 vaccine in patients with multiple myeloma.

Authors:  Toshiki Terao; Takeshi Yamashita; Hiroyuki Takamatsu; Kosei Matsue; Ami Fukumoto; Yuya Kamura; Daisuke Ikeda; Ayumi Kuzume; Rikako Tabata; Takafumi Tsushima; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Masahiro Doi; Yuka Umezawa; Yoshihito Otsuka
Journal:  Int J Hematol       Date:  2022-02-21       Impact factor: 2.319

6.  Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia.

Authors:  Toshiki Terao; Takashi Naduka; Daisuke Ikeda; Ami Fukumoto; Yuya Kamura; Ayumi Kuzume; Rikako Tabata; Takafumi Tsushima; Daisuke Miura; Kentaro Narita; Masami Takeuchi; Kosei Matsue
Journal:  Br J Haematol       Date:  2022-02-16       Impact factor: 8.615

7.  Daratumumab provides a survival benefit in relapsed and refractory Multiple Myeloma, independent of baseline clinical characteristics: A meta-analysis.

Authors:  Congcong Cao; Xin Zhou; Qun Ma
Journal:  Pharmacol Res Perspect       Date:  2021-08

8.  Dawn of Monitoring Regulatory T Cells in (Pre-)clinical Studies: Their Relevance Is Slowly Recognised.

Authors:  A Charlotte M T de Wolf; Carla A Herberts; Marcel H N Hoefnagel
Journal:  Front Med (Lausanne)       Date:  2020-04-02

Review 9.  Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma.

Authors:  Laurens E Franssen; Claudia A M Stege; Sonja Zweegman; Niels W C J van de Donk; Inger S Nijhof
Journal:  J Clin Med       Date:  2020-04-22       Impact factor: 4.241
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.